"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shack...
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
--------
1:20:53
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
--------
1:01:48
Ep170: David Schenkein on Investing in the Future of Biotech
David Schenkein, general partner at GV, on investing in the future of biotech.
--------
59:52
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
--------
1:02:28
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
España